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Metastasis of epithelial tumors critically depends on acquisition of a disseminating phenotype that allows
tumor cells to colonize distant organs. In this issue of Cancer Cell, Labelle et al. demonstrate that an epithe-
lial-mesenchymal-like transition can be induced by interaction between platelets and tumor cells.Host cell types provide cues that regulate
tumor metastasis, essentially at all stages
of tumor progression. Cells disseminating
from primary epithelial tumors use the
bloodstream and lymphatics to colonize
distant sites. The impact of tumor-host
interactions encountered within the
bloodstream has been explored far less
than that occurring in primary tumors
and distant lesions. There are primarily
three reasons: microenvironments within
the vasculature are difficult to access,
hard to define, and transient in nature.
While cancer patients often present with
conditions indicating activation of plate-
lets and the coagulation system, the role
of platelets in cancer dissemination is
only partially understood (Erpenbeck and
Scho¨n, 2010; Gay and Felding-Haber-
mann, 2011). In this issue of Cancer Cell,
Labelle et al. (2011) demonstrate a novel
role for platelets that profoundly impacts
the ability of blood borne tumor cells to
seed distant metastases. Direct platelet
signaling to tumor cells leads to en-
hanced metastasis through platelet re-
lease of transforming growth factor b
(TGF-b) which induces epithelial-mesen-chymal-like transition in tumor cells and
is critically enhanced through direct
tumor cell-platelet contact.
Platelets are key contributors to he-
mostasis, leukocyte trafficking during
inflammation, and maintenance of vessel
stability. A hallmark of platelet function
is the prevention of hemorrhage and
perpetuation of coagulation to form and
stabilize blood clots. Platelets are impli-
cated in supporting metastasis through
coherence with tumor cells, formation
of heteroaggregates that also include
leukocytes (La¨ubli et al., 2006), and pro-
teins of the coagulation system that pro-
vide a transient microenvironment, which
supports tumor cell survival and protec-
tion from immune elimination (Palumbo
et al., 2005).
As the links between platelets, coagula-
tion, and tumor metastasis coalesce,
platelet-specific factors and recipient sig-
naling mechanisms on tumor cells, im-
portant for malignancy, are still being
resolved in mouse models. Labelle et al.
(2011) now identify specific platelet factor
and signaling pathways evoked in tumor
cells that critically support metastasis.By conditioning tumor cells with platelets
in vitro, the authors elicit colon and breast
carcinoma cells to become more invasive
and mesenchymal-like and ultimately
more aggressive in an experimental lung
metastasis model. This enhanced me-
tastasis shows that the initial exposure
to platelets can reprogram tumor cells.
Thus, these results extend beyond docu-
mented contributions of platelets to tumor
cell arrest, survival, and immune evasion
en route tometastasis (Figure 1). Signaling
factors released from platelet granules
could directly affect tumor cell survival,
proliferation, or invasiveness during me-
tastasis. In a definitive and beautifully-
executed experiment, Labelle et al.
(2011) knockout expression of TGF-b1
specifically in megakaryocytes, and
hence in platelets, by generating a
TGF-b1 floxed/platelet factor 4 cremouse
model (Pf4-cre+; TGFb1fl/fl). The dramati-
cally diminished metastasis seen in mice
deficient in platelet TGF-b1 suggests that
tumor cell behavior is altered as a result
of platelet activation and release of alpha
granules. A lack of TGF-b1 in platelets
also delayed tumor cell extravasation inovember 15, 2011 ª2011 Elsevier Inc. 553
Figure 1. Steps in Hematogenous Metastasis that Are Critically Supported by Platelets
Platelets contribute to generating amicroenvironment for tumor cells within the bloodstream that supports
the metastatic process. Upon activation, platelets undergo a shape change and release granules that
contain growth factors, chemokines, and proteases. Activated platelets also increase their adhesiveness,
which fosters cohesion with tumor cells and leukocytes to form heteroaggregates which interact with the
endothelium as well as protect tumor cells from immune elimination. In this issue of Cancer Cell, Labelle
et al. (2011) identify a new role for platelets and a mechanism through which platelets interact with tumor
cells to become more invasive and capable of colonizing the lung. Platelets release TGF-b that induces
tumor cells to express genes for epithelial-mesenchymal-like transition while in contact with platelets.
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Previewsthe lung, indicating that platelets can
expedite tumor cell exit from the vascula-
ture and thus enhance lung metastasis.
This approach takes into account the
in vivo exposure of tumor cells within the
bloodstream to endogenous TGF-b1.
The use of megakaryocyte lineage-spe-
cific gene deletion distinguishes the
platelet source from that of many other
vascular cell types and from additional
platelet contributions to metastasis. Cor-
roborating this result, the authors show
that priming of cancer cells by platelets is
in part reversed by TGF-b1 depletion in
platelets. These data indicate that platelet
factors can act directly on tumor cells to
enhance metastasis.
TGF-b1 was previously shown to prime
metastasis to the lungs (Padua et al.,
2008). Labelle et al. (2011) therefore
define platelets as a source for TGF-b1
in addition to the well established tumor
stromal and induced autocrine TGF-b1
production in tumor cells (Yang et al.,
2010). Platelet-derived TGF-b1 has been
reported to suppress lysis of tumor cells
by natural killer cells in vitro (Kopp et al.,
2009). Factors released by platelets
may therefore alter the behavior of both
cancer and immune cells to enhance
the aggressiveness and survival of circu-
lating tumor cells. In agreement with this
concept, another platelet-released factor,
lysophosphatidic acid, has been shown
to impact metastasis. Platelet lysophos-
phatidic acid can induce tumor cell
signaling to promote bone metastasis
(Boucharaba et al., 2004). Although TGF-
b1 appears to be a major determinant554 Cancer Cell 20, November 15, 2011 ª20of lung metastasis, additional undefined
platelet factors may signal to tumor or
host cells, and thereby contribute to
metastasis in multiple organs.
Tumor cells entering the blood-
stream within a primary tumor coordi-
nate with stromal cells to invade
surrounding tissue, remodel its matrix,
and access the circulation. Activation of
epithelial-mesenchymal transition (EMT)
results in decreased intercellular adhe-
sion and cell polarity as well as an
increase in matrix remodeling and migra-
tion to promote metastasis (Kalluri and
Weinberg, 2009). Labelle et al. (2011)
contribute new insight by uncovering
that EMT can be activated by TGF-b
secreted from surrounding platelets.
The authors report that platelets trigger
activation of TGF-b/Smad signaling to
endow tumor cells with a more aggres-
sive phenotype. The interaction with
platelets likely synergizes with cues
received in the primary tumor to
generate, reinforce, and amplify an EMT
program that ultimately supports coloni-
zation of distant sites.
Several platelet receptors have been
reported to support metastasis. Labelle
et al. (2011) show that tumor cell contact
with a platelet pellet, but not platelet re-
leasate alone, primes an increase in
metastasis through induction of epithelial
to mesenchymal-like genes. This induc-
tion involves NF-kB pathway activation,
because inhibition of this pathway via
tumor cell-expressed IkBa super-
repressor reversed the priming effect of
platelets on invasion, mesenchymal-like11 Elsevier Inc.gene expression, and metastasis (Labelle
et al., 2011). Programming of cancer cell
aggressiveness thus involves coordina-
tion of cancer cell contact with platelets,
and signaling in response to platelet
releasate. The intersection between
TGF-b/Smad signaling with contact-
driven NF-kB pathways may cooperate
in promoting tumor malignancy. Future
studies using defined cancer cell systems
and transgenic mouse models will help
identify the functional interactions be-
tween tumor cells and platelets that drive
this pathway activity.
Together, Labelle et al. (2011) con-
tribute new insight into direct tumor cell-
platelet interactions that induce mesen-
chymal-like attributes in metastatic cells.
The study suggests that tumor cells,
which have left the primary tumor, con-
tinue to interact with and respond to
cues from changing host microenviron-
ments to establish distant lesions.
Discovery of platelet interaction and
their released TGF-b as enhancer of
metastatic activity defines potential new
therapeutic targets for prevention and
treatment of metastatic disease, possibly
without disturbing platelet functions in
hemostasis.REFERENCES
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